SCHEMBL433618

SCHEMBL433618

CON=C(COc1ccc(CO)cc1)c1ccc(OC)cc1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
KDM4E B2RXH2 1/20 0.49
FFAR1 O14842 2/20 0.47
MAPT P10636 4/20 0.46
GAA P10253 2/20 0.46
PKM P14618 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
ALDH1A1 P00352 2/20 0.45
PLA2G4B P0C869 1/20 0.45
NPC1 O15118 1/20 0.43
POLB P06746 1/20 0.43
RAB9A P51151 1/20 0.43
TDP1 Q9NUW8 1/20 0.42
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL433617 1.00 KMT2A (0.49) KMT2AMEN1SMN1; SMN2KDM4EFFAR1
SCHEMBL16179399 0.90 ALDH1A1 (0.47) KMT2AMEN1SMN1; SMN2KDM4EFFAR1
SCHEMBL16179401 0.90 ALDH1A1 (0.47) KMT2AMEN1SMN1; SMN2KDM4EFFAR1
SCHEMBL15239156 0.89 MEN1 (0.49) KMT2AMEN1SMN1; SMN2KDM4EFFAR1
SCHEMBL15239158 0.89 MEN1 (0.49) KMT2AMEN1SMN1; SMN2KDM4EFFAR1
SCHEMBL434119 0.88 FFAR1 (0.59) KMT2AMEN1SMN1; SMN2FFAR1MAPT
SCHEMBL10267037 0.88 FFAR1 (0.59) KMT2AMEN1SMN1; SMN2FFAR1MAPT
SCHEMBL434118 0.88 FFAR1 (0.59) KMT2AMEN1SMN1; SMN2FFAR1MAPT
SCHEMBL15239087 0.86 FFAR1 (0.44) KMT2AMEN1SMN1; SMN2FFAR1MAPT
SCHEMBL15239182 0.86 FFAR1 (0.44) KMT2AMEN1SMN1; SMN2FFAR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2595952-B1 AGONISTS OF GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2020-11-18 EP disclosed
US-9278915-B2 Agonists of GPR40 CONNEXIOS LIFE SCIENCES PVT LTD (IN) 2016-03-08 US disclosed
WO-2015028960-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AS GPR AGONISTS AND USES THEREOF Piramal Enterprises Limited (IN) 2015-03-05 WO disclosed
US-20130237571-A1 AGONISTS OF GPR40 Conexios Life Sciences PVT. LTD. (IN) 2013-09-12 US disclosed
EP-2595952-A1 AGONISTS OF GPR40 Connexios Life Sciences Pvt. Ltd. (IN) 2013-05-29 EP disclosed
WO-2012011125-A1 AGONISTS OF GPR40 CONNEXIOS LIFE SCIENCES PVT. LTD. (IN) 2012-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237571-A1 AGONISTS OF GPR40 GPR65, GPR55, GPR68 KMT2A 3880/4885MEN1 2828/4885SMN1; SMN2 2796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.